| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 83.7 | 73.5 |
| Profit before tax | 38.7 | 32.0 |
| Net income | 31.7 | 31.6 |
| EPS (diluted, $ a share) | $0.23 | $0.23 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +0.5% |
|---|---|
| Revenue, year on year | +13.9% |
| Operating margin | 42.3% |
10-Q filed with the SEC, NASDAQ: AUPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aurinia Pharmaceuticals Inc.: key numbers
- Share price
- $15.48Close, Nov 16
- Market cap
- $2.07B
- Shares outstanding
- 134MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aurinia Pharmaceuticals Inc.
All →Aurinia Pharmaceuticals Financial Results
Aurinia Pharmaceuticals reported Q3 2026 financial results with total revenue of $83.7 million, a 14% increase year-over-year, driven by $79.4 million in net product sales of LUPKYNIS. The company reported net income of $31.7 million and increased its full-year 2026 total revenue guidance to a range of $325 million to $330 million.